AVANT Leaps as it Licenses Bio-Terror Fighting Technology

Publish date:

Updated from 8:43 a.m.

AVANT Immunotherapeutics


was up 103.4% in preopen Instinet trading after the company said it had licensed its vaccine technology to U.S. Department of Defense contractor

DynPort Vaccine

as a countermeasure to the threat of biological warfare.

AVANT said the deal with DVC includes license fees, milestone payments and royalties of an undisclosed amount.

Also on the move was another vaccine developer, SIGA Technologies (SIGA) - Get Report. SIGA was up 12.8% in preopen Island trading.

SIGA announced in a release Monday that its president and CEO, Philip N. Sussman, had resigned for personal reasons. No replacement was identified.